Press Releases
Prior announcements are available on the ASX website.
August 9, 2017
ResApp Reports Preliminary Top-line Results from SMARTCOUGH-C Study for Diagnosis of Childhood Respiratory Disease using Cough Sounds
June 22, 2017
ResApp Provides Updated Australian Paediatric Study Results
June 19, 2017
ResApp Announces Completion of Enrolment in SMARTCOUGH-C Study
May 30, 2017
ResApp Provides SMARTCOUGH-C May Study Update
April 28, 2017
ResApp Licenses Additional Pneumonia Diagnostic Tool from UniQuest
April 19, 2017
ResApp Extends SMARTCOUGH-C Study
March 21, 2017
ResApp to Present at Upcoming Conferences in March
March 15, 2017
ResApp Provides SMARTCOUGH-C Study Update
January 10, 2017
ResApp Announces Expanded Research Collaboration with Massachusetts General Hospital
December 9, 2016
ResApp Initiates SMARTCOUGH-C Study Evaluating Efficacy of ResAppDx for Diagnosing Childhood Respiratory Disease
November 28, 2016
ResApp to Present at Wilsons Healthcare IT Conference
November 16, 2016
ResApp Receives Institutional Review Board Approval at Texas Children’s Hospital for SMARTCOUGH-C Study
November 11, 2016
ResApp Receives Institutional Review Board Approval at Massachusetts General Hospital for SMARTCOUGH-C Study
October 25, 2016
ResApp Receives Australian Emerging Company of the Year Award at the “Johnson & Johnson Innovation Industry Excellence Awards”
October 21, 2016
ResApp Receives First Institutional Review Board Approval for SMARTCOUGH-C Study
October 12, 2016
ResApp Wins Innovation Excellence Award at Tech23 2016
October 3, 2016
ResApp Announces Further Positive Results from Adult Clinical Study
September 15, 2016
ResApp Begins Field Evaluation with Leading Global Humanitarian Organisation
August 19, 2016
ResApp Wins Global Grand Finals at the 2016 Talent Unleashed Awards
August 18, 2016
ResApp Expands Diagnostic Application to the Management of Respiratory Disease
July 22, 2016
ResApp Wins Category at the 2016 Talent Unleashed Awards
July 20, 2016
ResApp Announces Massachusetts General Hospital as First US Clinical Study Site
June 30, 2016
ResApp Provides Update on US Clinical Study
June 21, 2016
ResApp Announces Positive Preliminary Results from Adult Clinical Study
June 7, 2016
ResApp Provides Australian Adult Study Enrolment Update
April 20, 2016
ResApp Completes Oversubscribed $12.5 Million Capital Raising to Expand Market Opportunity
March 31, 2016
ResApp Provides Updated Paediatric Clinical Study Results
March 14, 2016
ResApp Completes Successful Pre-Submission Meeting with the US FDA
March 2, 2016
ResApp Achieves Breakthrough Performance in Paediatric Clinical Study
February 26, 2016
Second Site Added to Adult Clinical Study
January 22, 2016
ResApp to Exhibit at the McKinsey Future of Digital Healthcare Conference in Dubai
December 31, 2015
ResApp Files Pre-Submission Package with the US FDA
December 14, 2015
ResApp Receives Approval to Begin Adult Study
November 10, 2015
Further Positive Preliminary Results from Clinical Study
November 4, 2015
ResApp to Exhibit at the McKinsey Global Integrated Care Conference in Sydney
October 22, 2015
ResApp’s Dr Abeyratne to present at the inaugural Pneumonia Innovations Summit in New York
September 30, 2015
Positive preliminary results from current clinical study for diagnosing respiratory disease
September 3, 2015
FDA Consultant Engagement
September 1, 2015
Clinical Study Update
August 12, 2015
Second Site Added To Clinical Study
July 31, 2015
Quarterly Commentary – Q2 2015
July 17, 2015
ResApp Appoints New Chairman, Dr Roger Aston
July 14, 2015
ResApp Shares Commence Trading on the ASX and Patient Enrolment Complete for Clinical Study
Brian Leedman
Executive Director and VP, Corporate Affairs
+61 412 281 780
brian@resapphealth.com.au
ResApp Health Limited
ABN 51 094 468 318
Headquarters: Level 8, 127 Creek St, Brisbane, QLD 4000
Registered Office: Level 24, 44 St Georges Tce, Perth, WA 6000
© 2017 ResApp Health Limited. All Rights Reserved.
+61 8 6211 5099
+61 8 9218 8875
General Information
Clinical Studies
Investor Relations
ResApp Health®, the ResApp Health logo and ResAppDx® are registered trademarks of ResApp Health Limited in the United States.
In the United States, ResAppDx is an investigational device and is not available for sale.